Antidote side effects compared: 3 drugs, 13,672 FDA adverse event reports
Members
| Drug | FAERS reports | Serious | Death outcome | Boxed warning | Top labeled signals | Unlabeled (unassessed) |
|---|---|---|---|---|---|---|
| Acetylcysteine | 9,365 | 89% | 1,754 | – | – | Bronchiectasis; Toxic epidermal necrolysis |
| Hydroxocobalamin | 4,118 | 91% | 311 | – | Acute kidney injury; Chromaturia; Lip swelling | Hyponatraemia; Swelling face |
| Fomepizole | 189 | 98% | 69 | – | – | Toxicity to various agents; Metabolic acidosis |
Class-wide signals (flagged in at least 2 of 3 members)
| Reaction | Members flagged | Median PRR | Reports (sum) | In label |
|---|---|---|---|---|
| Metabolic acidosis | 2/3 | 43.6 | 64 | 0/2 members' labels |
| Coagulopathy | 2/3 | 35.9 | 26 | 0/2 members' labels |
Member-specific signals (flagged in exactly one drug)
No strong single-member signals (n ≥ 50) in this class.
Common questions
Which antidote has the most FDA adverse event reports?
Acetylcysteine has the most FAERS co-reports in this class (9,365), followed by Hydroxocobalamin (4,118). Report volume tracks how widely and how long a drug has been used, and how much attention it has had, far more than its risk.
Which side effects are shared across antidote drugs?
Reaction terms flagged in at least half of the 3 members include metabolic acidosis, coagulopathy. A term shared across a class usually reflects the shared mechanism (or the shared patient population) rather than one product.
Does a FAERS signal mean the drug causes the reaction?
No. These are disproportionality signals from voluntary reports with no denominator. Each is screened against the FDA label (known vs unlabeled) on the drug pages; causality needs temporality, dose-response, plausibility and trial or cohort evidence.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, seriousness and death counts from openFDA count queries. Generated 2026-10-08. Not medical advice.